Search

US-20260125770-A1 - INFLAMMATORY DISORDER IN A FELIDAE

US20260125770A1US 20260125770 A1US20260125770 A1US 20260125770A1US-20260125770-A1

Abstract

The presently disclosed subject matter relates to an in vitro method for the diagnosis or follow-up of an inflammatory disorder in a Felidae. The presently disclosed subject matter also relates to compounds, and compositions thereof, for treating an inflammatory disorder in a Felidae.

Inventors

  • Xavier LANGON

Assignees

  • MARS, INCORPORATED

Dates

Publication Date
20260507
Application Date
20231013
Priority Date
20221021

Claims (16)

  1. 1 . A method for the diagnosis of an inflammatory disorder in a Felidae, comprising a step of determining the level of occurrence of Bacteroides vulgatus or Helicobacter canis in a digestive tract sample thereof, wherein: (a) an increase of the level of Bacteroides vulgatus is indicative of the occurrence of the inflammatory disorder, and/or (b) a decrease of the level of Helicobacter canis is indicative of the occurrence of the inflammatory disorder, and/or (c) an increase of the ratio level of Bacteroides vulgatus over Helicobacter canis , is/are indicative of the inflammatory disorder.
  2. 2 . The method of claim 1 , comprising a step of determining the level of occurrence of Bacteroides vulgatus in the digestive tract sample thereof.
  3. 3 . The method of claim 1 , comprising a step of determining the level of occurrence of Helicobacter canis in the digestive tract sample thereof.
  4. 4 . The method of claim 1 , comprising a step of determining the level of occurrence of Bacteroides vulgatus and Helicobacter canis in the digestive tract sample thereof.
  5. 5 . The method of claim 1 , wherein the inflammatory disorder is selected from the list consisting of: an allergic disorder, an inflammatory skin disorder, an inflammatory tract disorder, and a respiratory tract disorder.
  6. 6 . The method of claim 1 , wherein the inflammatory disorder is Feline atopic syndrome (FAS).
  7. 7 . The method of claim 1 , wherein the inflammatory disorder is Feline atopic skin syndrome (FASS), Flea allergy dermatitis (FAD), or Feline food allergy (FFA).
  8. 8 . The method of claim 7 , wherein the inflammatory disorder is Feline atopic skin syndrome (FASS).
  9. 9 . The method of claim 1 , wherein the inflammatory disorder is miliary dermatitis (MD), self-inflicted alopecia/hypotrichosis (SIAH), head and neck pruritus (HNP), or eosinophilic granuloma complex (EGC).
  10. 10 . The method of claim 1 , wherein the digestive tract sample is selected from the group consisting of a fecal sample, a gastric sample, a saliva sample, and fractions thereof.
  11. 11 . The method of claim 1 , wherein the Felidae is selected from the group consisting of cheetah, puma, jaguar, leopard, lion, lynx, liger, tiger, panther, bobcat, ocelot, smilodon, caracal, serval and cats.
  12. 12 . The method of claim 1 , wherein the Felidae is selected from the group consisting of: Abyssinian, Aegean, American Bobtail, American Curl, American Ringtail, American Shorthair, American Wirehair, Aphrodite Giant, Arabian Mau, Asian, Asian Semi-longhair, Australian Mist, Balinese, Bambino, Bengal, Birman, Bombay, Brazilian Shorthair, British Longhair, British Shorthair, Burmese, Burmilla, California Spangled, Chantilly-Tiffany, Chartreux, Chausie, Colorpoint Shorthair, Cornish Rex, Cymric, Manx Longhair, Long-haired Manx, Cyprus, Devon Rex, Donskoy, Don Sphynx, Dragon Li, Chinese Li Hua, Dwelf, Egyptian Mau, European Shorthair, Exotic Shorthair, Foldex, German Rex, Havana Brown, Highlander, Himalayan, Colorpoint Persian, Japanese Bobtail, Javanese, Colorpoint Longhair, Kanaani, Khao Manee, Kinkalow, Korat, Korean Bobtail, Korn Ja, Kurilian Bobtail, Kuril Islands Bobtail, Lambkin, LaPerm, Lykoi, Maine Coon, Manx, Mekong Bobtail, Minskin, Minuet, Munchkin, Nebelung, Norwegian Forest Cat, Ocicat, Ojos Azules, Oregon Rex, Oriental Bicolor, Oriental Longhair, Oriental Shorthair, Persian, Peterbald, Pixie-bob, Ragamuffin, Liebling, Ragdoll, Raas, Russian Blue, Russian White, Russian Black, Russian Tabby, Sam Sawet, Savannah, Scottish Fold, Selkirk Rex, Serengeti, Serrade Petit, Siamese, Siberian, Siberian Forest Cat, Neva Masquerade, Singapura, Snowshoe, Sokoke, Somali, Sphynx, Suphalak, Thai, Thai Lilac, Thai Blue Point, Thai Lilac Point, Tonkinese, Toybob, Toyger, Turkish Angora, Turkish Van, Turkish Vankedisi, Ukrainian Levkoy, and York Chocolate.
  13. 13 . The method of claim 1 , wherein the step of determining the level of occurrence of Bacteroides vulgatus or Helicobacter canis comprises detecting all or part of a nucleic acid sequence of said Bacteroides vulgatus or Helicobacter canis.
  14. 14 . A composition comprising a compound selected from the group consisting of: (a) a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid; (b) ciclosporin; (c) oclatinib; (d) H1-receptor blocking antihistamine; (e) essential fatty acid selected from the group consisting of: linoleic acid, linolenic acid and arachidonic acid; (f) palmitoylethanolamide (PEA); and (g) combinations thereof; wherein the amount of the compound is an amount effective for treating an inflammatory disorder in a Felidae.
  15. 15 . The composition of claim 14 , wherein the inflammatory disorder is Feline atopic skin syndrome (FASS).
  16. 16 . A method for treating an inflammatory disorder in a Felidae, comprising the steps of: a) determining an increased level of Bacteroides vulgatus in the digestive tract, a decreased level of Helicobacter canis in the digestive tract, and/or an increased ratio level of Bacteroides vulgatus over Helicobacter canis in the digestive tract of the felidae, in particular in a digestive tract sample of the felidae; and b) administering to the felidae at least one compound or composition selected from the group consisting of a corticosteroid, in particular a glucocorticoid or a mineralocorticosteroid, ciclosporin, oclatinib, H1-receptor blocking antihistamine, essential fatty acid selected from the group consisting of linoleic acid, linolenic acid and arachidonic acid, palmitoylethanolamide (PEAum), and combinations thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS The present application claims priority to European Application No. 22202920.9, filed on Oct. 21, 2022, the contents of which are hereby incorporated by reference in its entirety. SEQUENCE LISTING The instant application contains a Sequence Listings, which has been submitted in XML format via EFS-Web and is hereby incorporated by reference in its entirety. Said XML copy, created on Sep. 29, 2023, is named 069269_0650_SL.xml and is 2,757 bytes in size. TECHNICAL FIELD The presently disclosed subject matter relates to the field of diagnosis and follow-up of an inflammatory disorder in a Felidae, in particular of a pet animal such as a cat. More particularly, the presently disclosed subject matter relates to the field of diagnosis and follow-up of Feline atopic syndrome (FAS), which includes Feline atopic skin syndrome (FASS), Flea allergy dermatitis (FAD), Feline food allergy (FFA), and associated conditions. The presently disclosed subject matter further relates to compounds, and compositions thereof, for treating an inflammatory disorder in a Felidae. BACKGROUND The complex intestinal microbiome is widely investigated in humans since the last fifty years. Studies have shown that the microbiome can be affected by different environmental factors and diseases, including systemic inflammatory diseases, with major or minor effects. In humans, long standing diseases such as obesity, inflammatory bowel diseases, allergic rhinitis, and atopic dermatitis are reportedly linked with the microbiome, in a controversial causal manner. Current studies focus in understanding its preventive role during infancy and bacterial strains involved in adults with allergic status. In particular, atopic dermatitis is a chronic inflammatory skin condition, starting in early childhood and is usually the first manifestation of the atopic march. Maturation of an inappropriate T-helper type 2 (Th2) immune response that predominates at birth to a Th1 predominance in infancy and adulthood is conditional on the presence of commensal gut bacteria. The microbiome has a well-documented role in human atopic dermatitis, in particular the association of dysbiosis and an increase risk of atopy. American adults with allergies, especially to nuts and seasonal pollen, have low diversity, reduced Clostridiales, and increased Bacteroidales in their gut microbiota. This dysbiosis might be targeted to improve treatment or prevention of allergy (Hua et al; Allergy associations with the adult fecal microbiota: Analysis of the American Gut Project; EBioMedicine, 2016). Under certain conditions, it is hypothesized that this gut homeostasis condition is also disrupted in other non-human mammals. For example, dysbiosis may occur with a reduction of bacterial diversity, a loss of beneficial bacteria and an overgrowth of pathogens. Because microbial shifts are often noted with disease, it is thought that microbiome profiles may be used as biomarkers for diagnosis and/or monitoring in the future, as reported in the fecal microbiome of dogs (Lin et al.; An ambient temperature collection and stabilization strategy for canine microbiota studies; Nature, 2020). Inflammatory disorders, in particular those resulting from feline allergic diseases, are prevalent in cats (Halliwell et al.; Feline allergic diseases: introduction and proposed nomenclature; Veterinary Dermatology, 2021). Feline atopic skin syndrome (FASS) is an inflammatory and pruritic skin syndrome of cats manifested by a spectrum of reaction patterns, that may be associated with IgE antibodies to environmental allergens (Richard Halliwell; Immunopathogenesis of the feline atopic syndrome; Veterinary Dermatology, 2021). The cutaneous lesions of FASS are variable in appearance, and include miliary dermatitis (MD), self-inflicted alopecia/hypotrichosis (SIAH), head and neck pruritus (HNP) and eosinophilic granuloma complex (EGC) (Santoro et al.; Clinical signs and diagnosis of feline atopic syndrome: detailed guidelines for a correct diagnosis; Veterinary. Dermatology, 2021). In Felidae, the new consideration of gut microbiota role and the fast development of next-generation sequencing have also given access to these microbial data (Lyu et al.; Past, Present, and Future of Gastrointestinal Microbiota Research in Cats; Front. Microbiol., 2020). Similarly to other mammals, the vast majority of the gastrointestinal (GI) microbiota in cats (over 99%) is composed of the predominant bacterial phyla Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. One study has demonstrated a correlation between Feline Chronic Enteropathy severity and an increased Enterobacteriaceae (Simpson; Chapter 10—The Role of the Microbiota in Feline Inflammatory Bowel Disease; August's Consultations in Feline internal medicine, Vol. 7, 2016). In one study, an increase of Bifidobacteriales and Lactobacillaceae was further associated with feline immunodeficiency virus infection (Weese et al.